Purple Biotech Hits Milestone for Tri-Specific Antibody, Plans IND

Purple Biotech (NASDAQ: PPBT) announced a manufacturing milestone for IM1240, a CAPTN-3 tri-specific antibody targeting 5T4, CD3 and NKG2A. The company reports achieving a commercially viable yield and high-purity process for IM1240, validating CAPTN-3's scalability for complex tri-specific antibodies. IM1240 includes a protease-cleavable, albumin-bound cap intended to limit systemic CD3 activation and extend half-life, concentrating activity in the tumor microenvironment. The program is advancing toward first-in-human studies with an IND submission planned for 2026.

https://www.stocktitan.net/news/PPBT/purple-biotech-achieves-manufacturing-milestone-for-im1240-a-tri-6bfahp3305nh.html